Harrow Launches Recently Acquired Products Ilevro, Nevanec, and Maxidex in the US

Harrow announced the completion of the transfer to Harrow of the new drug applications (NDAs) for Ilevro (nepafenac ophthalmic suspension) 0.3%, Nevanec (nepafenac ophthalmic suspension) 0.1%, and Maxidex (dexamethasone ophthalmic suspension) 0.1%. These three FDA-approved ophthalmic medicines, which are now commercially available under the Harrow umbrella, were among the five products that Harrow purchased in January of 2023 and for which Harrow has been receiving net profits from unit sales during the NDA transfer process. Harrow expects to complete the transfer of the NDAs for the two remaining products, Vigamox (moxifloxacin hydrochloride ophthalmic solution) 0.5%, and Triesence (triamcinolone acetonide injectable suspension) 40 mg/ml, by year-end.

“We are delighted to have completed the NDA transfer process for Ilevro, Nevanec, and Maxidex earlier than our originally estimated 6-month period,” Mark L. Baum, Chief Executive Officer of Harrow, said in a company news release. “We can now implement our market access, marketing, inventory management, and national sales detailing strategies for each of these three products, and we expect to extend those efforts when the NDAs for the remaining two products, Vigamox and Triesence, are transferred later this year.

Product orders for Ilevro, Nevanec, and Maxidex can be made directly through Harrow’s dedicated customer service ordering partner, Cardinal’s Cordlogistics, which includes a wholesaler distribution system encompassing McKesson and AmerisourceBergen.